WOONSOCKET – MultiCell Technologies announced on Aug. 10 its updates on preclinical research results for MCT-465 and MCT-485, the first of a family of prospective cancer therapeutics based on the use of its patented signaling technology. MCT-465 and MCT-485 are being investigated as prospective treatments for primary liver cancer and triple-negative breast cancer.
The latest preclinical results for MCT-485 showed in vitro dose-effect cytotoxicity on several human hepatocellular carcinoma cell lines, according to the company. In contrast, MCT-465 showed no cytotoxicity or anti-proliferative effect, according to the company.
The research results support further mechanistic and in vivo studies exploring the safety, effectiveness and utility of MCT-465 and MCT-485 as novel therapeutic agents as a treatment for hepatocellular carcinoma and other cancers, according to MultiCell Technologies.
Hepatocellular carcinoma is the most common form of primary liver cancer and a leading cause of cancer death. Current pharmacological approaches for treatment have been very limited in their efficacy. •